BIIB068

BIIB068 is a potent, selective, reversible, and orally active small molecule inhibitor of Bruton's tyrosine kinase (BTK). It demonstrates high selectivity for BTK with an IC50 of 1 nM and a Kd of 0.3 nM, showing over 400-fold selectivity compared to other kinases[1][2][4]. The drug was developed by Biogen for the treatment of autoimmune diseases such as systemic lupus erythematosus (SLE), targeting BTK to modulate B cell activation and downstream immune responses implicated in autoantibody-driven disorders[2][7]. Preclinical studies showed that BIIB068 inhibits B cell, neutrophil, and monocyte activation without affecting T cell responses[4]. It was well tolerated in preclinical species and healthy human subjects at pharmacologically relevant doses[2][4].